Frequently Asked Questions
How does upadacitinib work?
Upadacitinib is an oral Janus kinase inhibitor. In the head-to-head HEADS UP and LEVEL UP trials, it showed superior efficacy over dupilumab, an interleukin-4 receptor alpha antagonist.
What did the LEVEL UP and HEADS UP analysis show about flares after switching from dupilumab?
No skin lesion flares occurred through 16 weeks in LEVEL UP (0/201) or HEADS UP (0/27). Itch flares occurred in 3.6% (5/139) of eligible patients in LEVEL UP and 4.8% (1/21) in HEADS UP.
How were skin lesion and itch flares defined?
Skin lesion flare was an increase of at least 6.6 points in EASI score, and itch flare was an increase of at least 4 points in WP-NRS score. Both were measured from the time of switching.
Mean Worst Pruritus Numerical Rating Scale (WP-NRS) scores at the switch were 3.9 (SD, 2.3) in LEVEL UP and 4.1 (SD, 2.7) in HEADS UP. Skin lesion flare was defined as an increase of at least 6.6 points in EASI score from the time of switching. Through 16 weeks, no skin lesion flares occurred in LEVEL UP (0/201) or HEADS UP (0/27), based on observed case data.¹
Itch Flares and Dose Escalation Data
Itch flare was defined as an increase of at least 4 points in WP-NRS score from the time of switching. A 4-point increase cannot occur from a score above 6 on the 0-to-10 scale. The itch flare analysis was therefore limited to patients with a WP-NRS score of 6 or lower at the switch.¹
Patients with 1 or more itch flares at any visit were counted once. Itch flares occurred in 3.6% (5/139) of patients in LEVEL UP and 4.8% (1/21) of patients in HEADS UP. In LEVEL UP, 52.7% of the 207 patients who switched to upadacitinib 15 mg remained on this dose without escalation.¹
In LEVEL UP, EASI was assessed at weeks 4 and 16 after the switch, and itch results relied on weekly averages from weeks 1 to 16. In HEADS UP, EASI and WP-NRS were assessed at weeks 4, 8, and 16.¹ The poster did not report safety data for the switch population.¹
The authors concluded the findings may help inform treatment-switch discussions with patients concerned about worsening skin lesions or itch during the transition from dupilumab to upadacitinib. The analysis was post hoc, and HEADS UP contributed a small subgroup of 28 patients.¹
References
- Zirwas MJ, Ruiz Dasilva D, Shahriari M, et al. Switching to upadacitinib monotherapy was associated with minimal or no flares following inadequate response to dupilumab in patients with moderate-to-severe atopic dermatitis. Presented at: The 2026 Fall Clinical Dermatology Conference; October 8–11, 2026; Las Vegas, NV. Poster DV-021148.
- Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults With moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047-1055. doi: 10.1001/jamadermatol.2021.3023
- Silverberg JI, Bunick CG, Hong HC, et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up). Br J Dermatol. 2024;192(1):36-45. doi: 10.1093/bjd/ljae404